FDA approves study of Alpha Tau's Alpha DaRT for recurrent cSCC treatment [Yahoo! Finance]
Alpha Tau Medical Ltd. - Ordinary Shares (DRTS)
Company Research
Source: Yahoo! Finance
Secondary efficacy objectives of the Alpha DaRT cancer therapy study will focus on progression-free survival, overall survival, and local control up to 12 months post-treatment. Additionally, the safety objective will involve monitoring any related adverse events. Alpha DaRT works by delivering highly potent alpha-irradiation directly into solid tumours using radium-224-impregnated sources. As the radium decays, its short-lived daughters are said to emit high-energy alpha particles for destroying the tumour. The limited diffusion of the alpha-emitting atoms is designed to primarily target the tumour while sparing surrounding healthy tissue. Alpha Tau Medical CEO Uzi Sofer said: “As we continue to progress in our ReSTART multicentre pivotal trial for recurrent cutaneous SCC, a number of investigators asked about the ability to treat immunocompromised patients, who are ineligible for the ReSTART trial. “Emory University is an important partner of ours and we are proud to wo
Show less
Read more
Impact Snapshot
Event Time:
DRTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRTS alerts
High impacting Alpha Tau Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
DRTS
News
- Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCCGlobeNewswire
- Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor CoGlobeNewswire
- Alpha Tau Medical Ltd. (NASDAQ: DRTS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Alpha Tau Medical Ltd. (NASDAQ: DRTS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $7.00 price target on the stock.MarketBeat
- Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
DRTS
Analyst Actions
- 8/20/24 - HC Wainwright
DRTS
Sec Filings
- 9/20/24 - Form 6-K
- 8/22/24 - Form 6-K
- 8/14/24 - Form 6-K
- DRTS's page on the SEC website